Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : Tevjf save search
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
stelara fda biosimilar approval teva
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Published: 2024-02-24 (Crawled : 04:20) - globenewswire.com
KMDA | $5.21 2.16% 19K
|
Health Technology
| Email alert
Add to watchlist
ALVO | $13.45 4.34% 170K
|
n/a
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
simlandi first biosimilar approval teva
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
Published: 2024-01-10 (Crawled : 09:00) - globenewswire.com
ALVO | $13.45 4.34% 170K
|
n/a
|
| O: -0.72%
H: 1.77%
C: -1.53%
KMDA | $5.21 2.16% 19K
|
Health Technology
|
| O: -0.66%
H: 0.71%
C: 0.17%
first biosimilar approval stelara
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
Published: 2023-11-17 (Crawled : 16:00) - biospace.com/
TEVA | $12.905 0.98% 5.9M
|
Health Technology
|
| O: 0.91%
H: 2.6%
C: 2.38%
HALO M | $38.23 1.11% 250K
|
Health Technology
|
| O: 0.94%
H: 1.8%
C: 0.1%
forteo approval teva
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Published: 2023-09-25 (Crawled : 08:00) - globenewswire.com
ALVO | $13.45 4.34% 170K
|
n/a
|
| O: 1.24%
H: 4.25%
C: -0.67%
KMDA | $5.21 2.16% 19K
|
Health Technology
|
| O: 1.16%
H: 1.98%
C: -0.38%
avt04 stelara biosimilar japan approval
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Published: 2023-08-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.45 4.34% 170K
|
n/a
|
| O: -0.93%
H: 3.75%
C: 2.39%
KMDA | $5.21 2.16% 19K
|
Health Technology
|
| O: 0.55%
H: 2.24%
C: 0.92%
avt02 approval egypt
Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio
Published: 2023-03-10 (Crawled : 23:00) - prnewswire.com
AMGN | $266.895 1.58% 950K
|
Health Technology
| Email alert
Add to watchlist
CTIC | $9.09 0.05% 11M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.2 510
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $166.43 1.08% 2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $93.81 1.34% 1.2M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.605 0.85% 790K
|
Health Technology
| Email alert
Add to watchlist
ADCT | $4.86 2.1% 120K
|
Health Technology
| Email alert
Add to watchlist
approval therapeutics growth market
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
Published: 2023-01-24 (Crawled : 10:00) - globenewswire.com
ALVO | $13.45 4.34% 170K
|
n/a
|
| O: -1.34%
H: 2.21%
C: 0.85%
KMDA | $5.21 2.16% 19K
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: -2.73%
avt02 approval
Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
Published: 2022-10-17 (Crawled : 10:00) - globenewswire.com
ALVO | $13.45 4.34% 170K
|
n/a
|
| O: 0.44%
H: 7.05%
C: 2.64%
KMDA | $5.21 2.16% 19K
|
Health Technology
|
| O: 2.74%
H: 0.89%
C: 0.0%
candidate biosimilar japan application approval
Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published: 2022-08-03 (Crawled : 04:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: -1.8%
H: 0.2%
C: 0.0%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
NPCE S | $14.135 0.96% 28K
|
Manufacturing
|
| O: 0.52%
H: 3.71%
C: -2.93%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.11%
H: 0.31%
C: -0.34%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: -0.29%
H: 0.24%
C: -0.58%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
BIIB | $192.68 1.13% 590K
|
Health Technology
|
| O: 0.41%
H: 3.35%
C: 1.71%
ACAD | $16.88 -1.11% 340K
|
Health Technology
|
| O: 2.47%
H: 2.8%
C: -2.67%
approval therapeutics growth market
Global Pharmaceutical API Manufacturing Market Report 2022-2030: Stringent Regulations for Approval of Pharmaceutical Drugs Restraining Growth
Published: 2022-04-12 (Crawled : 17:00) - prnewswire.com
AZNCF | $138.24 800
|
Health Technology
|
| O: -0.86%
H: 1.21%
C: 1.21%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.16%
H: 0.22%
C: 0.22%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: -0.48%
H: 0.09%
C: -0.68%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.77%
H: 0.99%
C: 0.49%
ALB | News | $114.53 2.44% 810K
|
Process Industries
|
| O: 1.31%
H: 2.06%
C: -1.76%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: -0.31%
H: 0.74%
C: -1.18%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -3.25%
H: 0.0%
C: 0.0%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -2.32%
H: 0.43%
C: -0.55%
report approval growth market drug
CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Published: 2022-01-31 (Crawled : 07:00) - prnewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
REGN | $894.71 0.08% 180K
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -2.34%
dupixent approval chmp children
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
Published: 2021-10-20 (Crawled : 22:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.08%
H: 0.41%
C: 0.41%
REGN | $894.71 0.08% 180K
|
Health Technology
|
| O: 0.31%
H: 1.14%
C: 0.87%
fda children approval dupixent
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
BSFC | $0.0822 27.64% 75M
|
Manufacturing
RWOD | $10.08 26.05% 5.6M
|
n/a
CHRO | $1.53 24.9% 100K
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
INSG | $2.98 23.14% 190K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.